CN114787182A - 工程化的白细胞介素-2受体β激动剂 - Google Patents

工程化的白细胞介素-2受体β激动剂 Download PDF

Info

Publication number
CN114787182A
CN114787182A CN202080066791.1A CN202080066791A CN114787182A CN 114787182 A CN114787182 A CN 114787182A CN 202080066791 A CN202080066791 A CN 202080066791A CN 114787182 A CN114787182 A CN 114787182A
Authority
CN
China
Prior art keywords
polypeptide
engineered
seq
leu
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080066791.1A
Other languages
English (en)
Chinese (zh)
Inventor
陈岩
赵克浩
克里斯蒂娜·斯旺森
珍娜·阮
内森·卡伦
塞缪尔·克莱门特·哈桑
江宁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eperi Biopharmaceutical Co ltd
Original Assignee
Eperi Biopharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eperi Biopharmaceutical Co ltd filed Critical Eperi Biopharmaceutical Co ltd
Publication of CN114787182A publication Critical patent/CN114787182A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202080066791.1A 2019-08-13 2020-08-13 工程化的白细胞介素-2受体β激动剂 Pending CN114787182A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962886148P 2019-08-13 2019-08-13
US62/886,148 2019-08-13
PCT/US2020/046244 WO2021030633A1 (en) 2019-08-13 2020-08-13 Engineered interleukin-2 receptor beta agonists

Publications (1)

Publication Number Publication Date
CN114787182A true CN114787182A (zh) 2022-07-22

Family

ID=72243240

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080066791.1A Pending CN114787182A (zh) 2019-08-13 2020-08-13 工程化的白细胞介素-2受体β激动剂

Country Status (8)

Country Link
US (1) US20230002466A1 (cg-RX-API-DMAC7.html)
EP (1) EP4013774A1 (cg-RX-API-DMAC7.html)
JP (2) JP7783164B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220044534A (cg-RX-API-DMAC7.html)
CN (1) CN114787182A (cg-RX-API-DMAC7.html)
AU (1) AU2020329290A1 (cg-RX-API-DMAC7.html)
CA (1) CA3147677A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021030633A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220140514A (ko) 2020-01-10 2022-10-18 브라이트 피크 테라퓨틱스 아게 변형된 il-2 폴리펩타이드 및 그의 용도
BR112022017656A2 (pt) * 2020-03-05 2022-10-18 Univ Leland Stanford Junior Variantes de il-2 concebidas
EP4251187A4 (en) 2020-11-25 2025-09-10 Xilio Dev Inc TUMOR-SPECIFIC CLASSIBLE LINKERS
IL304365B2 (en) 2021-03-31 2025-04-01 Hanmi Pharmaceutical Co Ltd A novel conjugate of an IL2 immunostimulatory analog and method of preparation thereof
EP4373848A2 (en) * 2021-07-22 2024-05-29 University of Dundee Therapeutic muteins
CN113603791A (zh) * 2021-08-11 2021-11-05 厦门目青股权投资合伙企业(有限合伙) 一种融合蛋白及其应用
WO2023220597A1 (en) * 2022-05-10 2023-11-16 Elpis Biopharmaceuticals Engineered interleukin-2 receptor beta reduced-binding agonist
WO2025010341A2 (en) * 2023-07-05 2025-01-09 The Trustees Of Dartmouth College Cytokine hybrid proteins and methods related thereto
WO2025151752A1 (en) 2024-01-10 2025-07-17 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080025947A1 (en) * 2006-07-06 2008-01-31 Merck Patent Gmbh Methods for enhancing the efficacy of IL-2 mediated immune responses
CN107207603A (zh) * 2015-02-03 2017-09-26 吉安特科技股份有限公司 趋化因子‑免疫球蛋白融合多肽,其组合物、制备方法以及用途
CN109553688A (zh) * 2012-12-05 2019-04-02 生控基因疫苗股份有限公司 用作诱发抗原特异性t细胞反应的免疫原性增强剂的融合蛋白

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4604377A (en) 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
IL131016A (en) 1997-01-21 2004-12-15 Gen Hospital Corp Selection of proteins using RNA-protein blends
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
CN102816241B (zh) 2004-02-09 2015-07-22 人类基因科学公司 清蛋白融合蛋白
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
WO2012088446A1 (en) * 2010-12-22 2012-06-28 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
CN105440123B (zh) * 2011-02-10 2020-10-09 罗切格利卡特公司 突变体白介素-2多肽
WO2012119093A1 (en) * 2011-03-03 2012-09-07 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
JP6592505B2 (ja) * 2014-04-24 2019-10-16 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー インターロイキン−2のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト
TWI833684B (zh) * 2015-06-25 2024-03-01 美商生物細胞基因治療有限公司 嵌合抗原受體(car)、組合物及其使用方法
US12522640B2 (en) * 2018-07-24 2026-01-13 BioNTech SE IL2 agonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080025947A1 (en) * 2006-07-06 2008-01-31 Merck Patent Gmbh Methods for enhancing the efficacy of IL-2 mediated immune responses
CN109553688A (zh) * 2012-12-05 2019-04-02 生控基因疫苗股份有限公司 用作诱发抗原特异性t细胞反应的免疫原性增强剂的融合蛋白
CN107207603A (zh) * 2015-02-03 2017-09-26 吉安特科技股份有限公司 趋化因子‑免疫球蛋白融合多肽,其组合物、制备方法以及用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ARON M. LEVIN: "EXPLOITING A NATURAL CONFORMATIONAL SWITCH TO ENGINEER AN INTERLEUKIN-2 SUPERKINE", NATURE, pages 529 - 533 *

Also Published As

Publication number Publication date
JP2022544785A (ja) 2022-10-21
WO2021030633A1 (en) 2021-02-18
JP7783164B2 (ja) 2025-12-09
CA3147677A1 (en) 2021-02-18
US20230002466A1 (en) 2023-01-05
KR20220044534A (ko) 2022-04-08
AU2020329290A1 (en) 2022-03-24
JP2026032136A (ja) 2026-02-25
EP4013774A1 (en) 2022-06-22

Similar Documents

Publication Publication Date Title
JP7783164B2 (ja) 改変インターロイキン2受容体ベータアゴニスト
JP7098725B2 (ja) 二重特異性2+1コントースボディ
US20230227584A1 (en) Bispecific antibodies comprising a modified c-terminal crossfab fragment
JP2024138240A (ja) 新規の二重特異性アゴニスト4-1bb抗原結合分子
TWI633121B (zh) 雙特異性活化t細胞之抗原結合分子
EP3035956B1 (en) Bi-specific monovalent diabodies that are capable of binding to gpa33 and cd3, and uses thereof
CN103492411B (zh) 突变体白介素-2多肽
JP2023529981A (ja) 免疫活性化Fcドメイン結合分子
KR20210083260A (ko) 다가 IgM- 및 IgA-Fc 기반 결합 분자
JP2017536121A (ja) FolR1及びCD3を標的とする二重特異性抗体
US20240376171A1 (en) Protease-activated polypeptides
JP2016515389A (ja) Fap及びdr5に特異的な二重特異性抗体、dr5に特異的な抗体並びに使用の方法
JP2023509952A (ja) 新規4-1bbl三量体含有抗原結合分子
JP2020515541A (ja) 共刺激性tnf受容体に対する二重特異性抗原結合分子
JP2023529982A (ja) プロテアーゼ活性化型t細胞二重特異性抗体
CN116635403A (zh) pH依赖性突变型白细胞介素-2多肽
CN121646609A (zh) Tnf超家族成员免疫细胞因子及其用途
US20250326813A1 (en) Engineered interleukin-2 receptor beta reduced-binding agonist
HK40076453A (en) Engineered interleukin-2 receptor beta agonists
CN114867751B (zh) 4-1bb和ox40结合蛋白及相关组合物和方法、抗-4-1bb抗体、抗-ox40抗体
HK40103919A (en) Protease-activated polypeptides
CN121343001A (zh) 一种融合蛋白及其用途
HK40070142A (en) New 4-1bbl trimer-containing antigen binding molecules
HK40078517A (en) 4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40076453

Country of ref document: HK